Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 14/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 6/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772437 | 1.00 | IMPDH2 (0.35) | IMPDH2IMPDH1GSK3BAAK1NPC1 | |
| SCHEMBL5779016 | 0.87 | IMPDH2 (0.39) | IMPDH2IMPDH1AAK1NPC1RAB9A | |
| SCHEMBL5779013 | 0.87 | IMPDH2 (0.39) | IMPDH2IMPDH1AAK1NPC1RAB9A | |
| SCHEMBL5779782 | 0.83 | LMNA (0.40) | IMPDH2IMPDH1GSK3BAAK1NPC1 | |
| SCHEMBL5779785 | 0.83 | LMNA (0.40) | IMPDH2IMPDH1GSK3BAAK1NPC1 | |
| SCHEMBL5778422 | 0.83 | RAB9A (0.49) | IMPDH2NPC1RAB9APOLBMAPT | |
| SCHEMBL5778054 | 0.78 | MAOA (0.52) | IMPDH2NPC1RAB9APOLBMAPT | |
| SCHEMBL5778057 | 0.78 | MAOA (0.52) | IMPDH2NPC1RAB9APOLBMAPT | |
| SCHEMBL5780415 | 0.76 | PKM (0.35) | IMPDH2IMPDH1AAK1NPC1RAB9A | |
| SCHEMBL5779118 | 0.76 | MAPT (0.44) | NPC1RAB9APOLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | IMPDH2 4694/4885IMPDH1 4461/4885GSK3B 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.